查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1507174

癌症免疫治疗市场、占有率、规模、趋势、行业分析报告：依类型、依应用、依最终用户、依地区、依细分市场、预测，2024-2032年

Cancer Immunotherapy Market Share, Size, Trends, Industry Analysis Report, By Type (Monoclonal Antibodies, Cancer Vaccines, Check Point Inhibitors & Immunomodulators); By Application; By End-User; By Region; Segment Forecast, 2024 - 2032
出版日期: | 出版商: Polaris Market Research | 英文 118 Pages | 商品交期: 最快1-2个工作天内

价格

根据Polaris Market Research的最新研究，预计到2032年，全球癌症免疫治疗市场规模将达到2,646.3亿美元。本研究报告提供了对当前市场动态的详细洞察，并对未来市场成长进行了分析。

由于癌症盛行率不断上升、新疗法的疗效和精确度不断提高、标靶疗法的采用不断增加以及新药开发的研究和开发活动不断增加，癌症免疫疗法市场不断成长。根据 NCT 註册中心截至2020年 9月 8 日的资料，全球有超过 1,000 项使用免疫疗法治疗癌症的临床试验进行，处于不同的开发阶段。随着这些治疗方法的开发取得进展，如果临床试验继续产生积极的结果，可以期待新的有效的癌症免疫疗法的出现。

癌症免疫疗法的研发在发展中国家面临重大挑战，由于成本高昂，很难获得足够的治疗经费。进行创新研究需要大量投入，这也是一个大问题。癌症免疫疗法的高成本阻碍了大公司进入这个市场，获利前景仍不确定。这些因素阻碍了癌症免疫治疗市场的成长。

免疫学的进步在癌症免疫治疗市场的成长和扩张中发挥着非常重要的作用。免疫学是研究免疫系统及其对各种疾病的反应的学科，近年来取得了长足的进步。这些进展使人们更了解癌细胞和免疫系统之间复杂的相互作用，为开发创新免疫疗法铺平了道路，彻底改变癌症治疗。对免疫学的日益深入的了解也促进了学术界、製药公司和研究机构之间的合作。这些合作加快癌症免疫治疗领域的药物开发和临床试验的步伐。科学家、临床医生和行业领导者的共同努力创造了一系列强大的新型免疫疗法，为各种癌症类型的患者带来了希望。

癌症免疫治疗市场报告亮点

2023年，单株抗体因其针对癌细胞或免疫细胞上特定分子的特殊能力而在全球市场中获得了很大占有率。这种有针对性的方法使免疫系统能够更有效地识别和对抗癌症，使单株抗体成为全球市场的主导区隔。

由于医疗保健支出不断增加，世界各地医院和诊所免疫治疗药物的使用增加，预计医院行业在几年内将以显着的年复合成长率成长。

北美在全球市场中占有压倒性的占有率，但这是因为该地区的患者更容易获得先进的癌症免疫治疗，并且有知名公司进入该市场，这是由于政府机构和非机构的大量投资。

目录

第1章 简介

第2章 执行摘要

第3章 研究方法

第4章 全球癌症免疫治疗市场洞察

  • 最终用户快照
  • 癌症免疫治疗市场动态
    • 推动因素和机会
      • 癌症患者的发生率不断增加
      • 免疫学的进展
    • 抑制因素和挑战
      • 治疗费用高昂
  • 波特五力分析
  • PESTEL 分析
  • 癌症免疫治疗市场的最终用户趋势
  • 价值链分析
  • 新冠肺炎（COVID-19）影响分析

第5章 全球癌症免疫治疗市场：依类型

  • 主要发现
  • 简介
  • 单株抗体
  • 癌症疫苗
  • 检查点抑制剂和免疫调节剂

第6章 全球癌症免疫治疗市场：依用途

  • 主要发现
  • 简介
  • 肺癌
  • 乳癌
  • 大肠癌
  • 恶性黑色素瘤
  • 摄护腺癌
  • 头颈癌
  • 其他

第7章 全球癌症免疫治疗市场：依最终用户

  • 主要发现
  • 简介
  • 医院
  • 诊所
  • 癌症研究中心

第8章 全球癌症免疫治疗市场：地区

  • 主要发现
  • 简介
    • 癌症免疫治疗市场评估：地区，2019-2032
  • 北美
    • 北美：依形态，2019-2032年
    • 北美：依最终使用者，2019-2032年
    • 北美：依用途，2019-2032年
    • 美国
    • 加拿大
  • 欧洲
    • 欧洲：依类型，2019-2032年
    • 欧洲：依最终使用者，2019-2032年
    • 欧洲：依用途，2019-2032年
    • 英国
    • 法国
    • 德国
    • 义大利
    • 西班牙
    • 荷兰
    • 俄罗斯
  • 亚太地区
    • 亚太地区：依类型，2019-2032年
    • 亚太地区：依最终使用者，2019-2032年
    • 亚太地区：依用途，2019-2032年
    • 中国
    • 印度
    • 马来西亚
    • 日本
    • 印尼
    • 韩国
  • 中东、非洲
    • 中东、非洲：依类型，2019-2032年
    • 中东和非洲：依最终用户，2019-2032年
    • 中东和非洲：依用途，2019-2032年
    • 沙乌地阿拉伯
    • 阿拉伯联合大公国
    • 以色列
    • 南非
  • 拉丁美洲
    • 拉丁美洲：依类型，2019-2032年
    • 拉丁美洲：依最终使用者，2019-2032年
    • 拉丁美洲：依用途，2019-2032年
    • 墨西哥
    • 巴西
    • 阿根廷

第9章 竞争态势

  • 扩张与收购分析
    • 扩张
    • 收购
  • 伙伴关係/协作/协定/揭露

第10章 公司简介

  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca
  • Bayer AG
  • Bristol Myers Squibb
  • Eli Lilly
  • F. Hoffmann-La Roche Ltd
  • Merck KGaA
  • Novartis AG
  • OSE Immunotherapeutics
Product Code: PM1652

The global cancer immunotherapy market size is expected to reach USD 264.63 Billion by 2032, according to a new study by Polaris Market Research. The report "Cancer Immunotherapy Market Share, Size, Trends, Industry Analysis Report, By Type (Monoclonal Antibodies, Cancer Vaccines, Check Point Inhibitors & Immunomodulators); By Application; By End-User; By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The cancer immunotherapy market is growing due to the increasing incidence of cancer, the expanding effectiveness and accuracy of newer therapies, the rising adoption of target therapy, and increasing R&D activities for new drug development. Over 1,000 clinical trials for treating cancer with immune-based therapies are currently underway worldwide in various phases of development, as per the NCT Registry as of September 8, 2020. With the ongoing development of these therapies, players can expect the emergence of new and effective immunotherapies for cancer, provided trials continue to yield positive results.

The research and development of cancer immunotherapy is faced with a significant challenge in developing countries due to its high cost, making it difficult for treatment to receive adequate funding. Substantial investment is required for implementing innovative research, which is also a major concern. Due to the high cost of cancer immunotherapy, major companies are hesitant to enter this market, and their profitability prospects remain uncertain. These factors collectively hinder the growth of the cancer immunotherapy market.

Advances in immunology have played a pivotal role in driving the growth and expansion of the cancer Immunotherapy market. Immunology, the study of the immune system and its response to various diseases, has witnessed significant breakthroughs in recent years. These advancements have led to a deeper understanding of the complex interactions between cancer cells and the immune system, paving the way for the development of innovative immunotherapies that are revolutionizing cancer treatment. The growing understanding of immunology has also fostered collaboration between academia, pharmaceutical companies, and research institutions. These collaborations have accelerated the pace of drug development and clinical trials in the field of cancer Immunotherapy. The collective efforts of scientists, clinicians, and industry leaders have resulted in a robust pipeline of novel immunotherapies, offering hope to patients with various cancer types.

Cancer Immunotherapy Market Report Highlights

In 2023, monoclonal antibodies gained a significant share in the global market due to their specialized ability to target specific molecules on either cancer cells or immune cells. This targeted approach facilitated the immune system's recognition and combat of cancer more effectively, making monoclonal antibodies the dominant segment in the global market.

The hospital segment is anticipated to grow with a significant CAGR in the forecasted years owing to increased healthcare expenditures, which have led to a rise in the use of Immunotherapy drugs in hospitals and clinics worldwide.

In the global market, North America dominated the market due to the increased accessibility of advanced cancer immunotherapies for patients in the region, the presence of notable market players, and the substantial investments made by both governmental and non-governmental organizations in cancer immunotherapy research and development.

The global key market players include Amgen Inc., Astellas Pharma Inc., AstraZeneca, Bayer AG, Bristol Myers Squibb, Eli Lilly, F. Hoffmann-La Roche Ltd, Merck KGaA, Novartis AG, OSE Immunotherapeutics, etc.

Polaris Market Research has segmented the cancer immunotherapy market report based on type, application, end-user, and region:

Cancer Immunotherapy, Type Outlook (Revenue - USD Billion, 2019 - 2032)

  • Monoclonal Antibodies
  • Cancer Vaccines
  • Check Point Inhibitors & Immunomodulators

Cancer Immunotherapy, Application Outlook (Revenue - USD Billion, 2019 - 2032)

  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Melanoma
  • Prostate Cancer
  • Head & Neck Cancer
  • Others

Cancer Immunotherapy, End-User Outlook (Revenue - USD Billion, 2019 - 2032)

  • Hospitals
  • Clinics
  • Cancer Research Centers

Cancer Immunotherapy, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Austria
  • Netherlands
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Australia
  • Rest of APAC
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa
  • Rest of MEA

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Cancer Immunotherapy Market Insights

  • 4.1. Cancer Immunotherapy Market - End-User Snapshot
  • 4.2. Cancer Immunotherapy Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising prevalence of cancer patients
      • 4.2.1.2. Advances in immunology
      • 4.2.1.3. Restraints and Challenges
      • 4.2.1.4. High Treatment Cost
    • 4.2.2. Porter's Five Forces Analysis
    • 4.2.3. Bargaining Power of Suppliers (Moderate)
    • 4.2.4. Threats of New Entrants: (Low)
    • 4.2.5. Bargaining Power of Buyers (Moderate)
    • 4.2.6. Threat of Substitute (Moderate)
    • 4.2.7. Rivalry among existing firms (High)
  • 4.3. PESTEL Analysis
  • 4.4. Cancer Immunotherapy Market End-User Trends
  • 4.5. Value Chain Analysis
  • 4.6. COVID-19 Impact Analysis

5. Global Cancer Immunotherapy Market, by Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
  • 5.3. Monoclonal Antibodies
    • 5.3.1. Global Cancer Immunotherapy Market, by Monoclonal Antibodies, by Region, 2019-2032 (USD Billion)
  • 5.4. Cancer Vaccines
    • 5.4.1. Global Cancer Immunotherapy Market, by Cancer Vaccines, by Region, 2019-2032 (USD Billion)
  • 5.5. Check Point Inhibitors & Immunomodulators
    • 5.5.1. Global Cancer Immunotherapy Market, by Check Point Inhibitors & Immunomodulators, by Region, 2019-2032 (USD Billion)

6. Global Cancer Immunotherapy Market, by Application

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
  • 6.3. Lung Cancer
    • 6.3.1. Global Cancer Immunotherapy Market, by Lung Cancer, by Region, 2019-2032 (USD Billion)
  • 6.4. Breast Cancer
    • 6.4.1. Global Cancer Immunotherapy Market, by Breast Cancer, by Region, 2019-2032 (USD Billion)
  • 6.5. Colorectal Cancer
    • 6.5.1. Global Cancer Immunotherapy Market, by Colorectal Cancer, by Region, 2019-2032 (USD Billion)
  • 6.6. Melanoma
    • 6.6.1. Global Cancer Immunotherapy Market, by Melanoma, by Region, 2019-2032 (USD Billion)
  • 6.7. Prostate Cancer
    • 6.7.1. Global Cancer Immunotherapy Market, by Prostate Cancer, by Region, 2019-2032 (USD Billion)
  • 6.8. Head & Neck Cancer
    • 6.8.1. Global Cancer Immunotherapy Market, by Head & Neck Cancer, by Region, 2019-2032 (USD Billion)
  • 6.9. Others
    • 6.9.1. Global Cancer Immunotherapy Market, by Others, by Region, 2019-2032 (USD Billion)

7. Global Cancer Immunotherapy Market, by End-User

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
  • 7.3. Hospitals
    • 7.3.1. Global Cancer Immunotherapy Market, by Hospitals, By Region, 2019-2032 (USD Billion)
  • 7.4. Clinics
    • 7.4.1. Global Cancer Immunotherapy Market, by Clinics, By Region, 2019-2032 (USD Billion)
  • 7.5. Cancer Research Centers
    • 7.5.1. Global Cancer Immunotherapy Market, by Cancer Research Centers, By Region, 2019-2032 (USD Billion)

8. Global Cancer Immunotherapy Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Cancer Immunotherapy Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 8.3. Cancer Immunotherapy Market - North America
    • 8.3.1. North America: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
    • 8.3.2. North America: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
    • 8.3.3. North America: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
    • 8.3.4. Cancer Immunotherapy Market - U.S.
      • 8.3.4.1. U.S.: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
      • 8.3.4.2. U.S.: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
      • 8.3.4.3. U.S.: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
    • 8.3.5. Cancer Immunotherapy Market - Canada
      • 8.3.5.1. Canada: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
      • 8.3.5.2. Canada.: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
      • 8.3.5.3. Canada: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
  • 8.4. Cancer Immunotherapy Market - Europe
    • 8.4.1. Europe: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
    • 8.4.2. Europe.: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
    • 8.4.3. Europe: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
    • 8.4.4. Cancer Immunotherapy Market - UK
      • 8.4.4.1. UK: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
      • 8.4.4.2. UK.: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
      • 8.4.4.3. UK: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
    • 8.4.5. Cancer Immunotherapy Market - France
      • 8.4.5.1. France: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
      • 8.4.5.2. France.: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
      • 8.4.5.3. France: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
    • 8.4.6. Cancer Immunotherapy Market - Germany
      • 8.4.6.1. Germany: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
      • 8.4.6.2. Germany.: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
      • 8.4.6.3. Germany: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
    • 8.4.7. Cancer Immunotherapy Market - Italy
      • 8.4.7.1. Italy: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
      • 8.4.7.2. Italy.: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
      • 8.4.7.3. Italy: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
    • 8.4.8. Cancer Immunotherapy Market - Spain
      • 8.4.8.1. Spain: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
      • 8.4.8.2. Spain.: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
      • 8.4.8.3. Spain: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
    • 8.4.9. Cancer Immunotherapy Market - Netherlands
      • 8.4.9.1. Netherlands: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
      • 8.4.9.2. Netherlands.: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
      • 8.4.9.3. Netherlands: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
    • 8.4.10. Cancer Immunotherapy Market - Russia
      • 8.4.10.1. Russia: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
      • 8.4.10.2. Russia.: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
      • 8.4.10.3. Russia: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
  • 8.5. Cancer Immunotherapy Market - Asia Pacific
    • 8.5.1. Asia Pacific: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
    • 8.5.2. Asia Pacific.: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
    • 8.5.3. Asia Pacific: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
    • 8.5.4. Cancer Immunotherapy Market - China
      • 8.5.4.1. China: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
      • 8.5.4.2. China.: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
      • 8.5.4.3. China: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
    • 8.5.5. Cancer Immunotherapy Market - India
      • 8.5.5.1. India: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
      • 8.5.5.2. India.: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
      • 8.5.5.3. India: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
    • 8.5.6. Cancer Immunotherapy Market - Malaysia
      • 8.5.6.1. Malaysia: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
      • 8.5.6.2. Malaysia.: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
      • 8.5.6.3. Malaysia: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
    • 8.5.7. Cancer Immunotherapy Market - Japan
      • 8.5.7.1. Japan: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
      • 8.5.7.2. Japan.: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
      • 8.5.7.3. Japan: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
    • 8.5.8. Cancer Immunotherapy Market - Indonesia
      • 8.5.8.1. Indonesia: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
      • 8.5.8.2. Indonesia.: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
      • 8.5.8.3. Indonesia: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
    • 8.5.9. Cancer Immunotherapy Market - South Korea
      • 8.5.9.1. South Korea: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
      • 8.5.9.2. South Korea.: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
      • 8.5.9.3. South Korea: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
  • 8.6. Cancer Immunotherapy Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
    • 8.6.2. Middle East & Africa.: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
    • 8.6.3. Middle East & Africa: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
    • 8.6.4. Cancer Immunotherapy Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
      • 8.6.4.2. Saudi Arabia.: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
    • 8.6.5. Cancer Immunotherapy Market - UAE
      • 8.6.5.1. UAE: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
      • 8.6.5.2. UAE.: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
      • 8.6.5.3. UAE: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
    • 8.6.6. Cancer Immunotherapy Market - Israel
      • 8.6.6.1. Israel: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
      • 8.6.6.2. Israel.: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
      • 8.6.6.3. Israel: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
    • 8.6.7. Cancer Immunotherapy Market - South Africa
      • 8.6.7.1. South Africa: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
      • 8.6.7.2. South Africa.: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
      • 8.6.7.3. South Africa: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
  • 8.7. Cancer Immunotherapy Market - Latin America
    • 8.7.1. Latin America: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
    • 8.7.2. Latin America.: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
    • 8.7.3. Latin America: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
    • 8.7.4. Cancer Immunotherapy Market - Mexico
      • 8.7.4.1. Mexico: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
      • 8.7.4.2. Mexico.: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
      • 8.7.4.3. Mexico: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
    • 8.7.5. Cancer Immunotherapy Market - Brazil
      • 8.7.5.1. Brazil: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
      • 8.7.5.2. Brazil.: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
      • 8.7.5.3. Brazil: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
    • 8.7.6. Cancer Immunotherapy Market - Argentina
      • 8.7.6.1. Argentina: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
      • 8.7.6.2. Argentina.: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
      • 8.7.6.3. Argentina: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. Amgen Inc.
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Astellas Pharma Inc.
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. AstraZeneca
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Bayer AG
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Bristol Myers Squibb
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Eli Lilly
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. F. Hoffmann-La Roche Ltd
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Merck KGaA
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Novartis AG
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. OSE Immunotherapeutics
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development

List of Tables

  • Table 1 Global Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
  • Table 2 Global Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
  • Table 3 Global Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
  • Table 4 Cancer Immunotherapy Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 5 North America: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
  • Table 6 North America: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
  • Table 7 North America: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
  • Table 8 U.S.: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
  • Table 9 U.S.: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
  • Table 10 U.S.: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
  • Table 11 Canada: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
  • Table 12 Canada: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
  • Table 13 Canada: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
  • Table 14 Europe: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
  • Table 15 Europe: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
  • Table 16 Europe: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
  • Table 17 UK: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
  • Table 18 UK: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
  • Table 19 UK: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
  • Table 20 France: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
  • Table 21 France: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
  • Table 22 France: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
  • Table 23 Germany: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
  • Table 24 Germany: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
  • Table 25 Germany: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
  • Table 26 Italy: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
  • Table 27 Italy: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
  • Table 28 Italy: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
  • Table 29 Spain: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
  • Table 30 Spain: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
  • Table 31 Spain: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
  • Table 32 Netherlands: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
  • Table 33 Netherlands: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
  • Table 34 Netherlands: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
  • Table 35 Russia: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
  • Table 36 Russia: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
  • Table 37 Russia: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
  • Table 38 Asia Pacific: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
  • Table 39 Asia Pacific: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
  • Table 40 Asia Pacific: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
  • Table 41 China: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
  • Table 42 China: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
  • Table 43 China: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
  • Table 44 India: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
  • Table 45 India: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
  • Table 46 India: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
  • Table 47 Malaysia: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
  • Table 48 Malaysia: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
  • Table 49 Malaysia: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
  • Table 50 Japan: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
  • Table 51 Japan: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
  • Table 52 Japan: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
  • Table 53 Indonesia: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
  • Table 54 Indonesia: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
  • Table 55 Indonesia: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
  • Table 56 South Korea: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
  • Table 57 South Korea: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
  • Table 58 South Korea: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
  • Table 59 Middle East & Africa: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
  • Table 60 Middle East & Africa: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
  • Table 61 Middle East & Africa: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
  • Table 62 Saudi Arabia: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
  • Table 63 Saudi Arabia: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
  • Table 64 Saudi Arabia: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
  • Table 65 UAE: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
  • Table 66 UAE: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
  • Table 67 UAE: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
  • Table 68 Israel: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
  • Table 69 Israel: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
  • Table 70 Israel: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
  • Table 71 South Africa: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
  • Table 72 South Africa: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
  • Table 73 South Africa: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
  • Table 74 Latin America: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
  • Table 75 Latin America: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
  • Table 76 Latin America: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
  • Table 77 Mexico: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
  • Table 78 Mexico: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
  • Table 79 Mexico: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
  • Table 80 Brazil: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
  • Table 81 Brazil: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
  • Table 82 Brazil: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)
  • Table 83 Argentina: Cancer Immunotherapy Market, by Type, 2019-2032 (USD Billion)
  • Table 84 Argentina: Cancer Immunotherapy Market, by Application, 2019-2032 (USD Billion)
  • Table 85 Argentina: Cancer Immunotherapy Market, by End-User, 2019-2032 (USD Billion)

List of Figures

  • Figure 1. Global Cancer Immunotherapy Market, 2019-2032 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Application
  • Figure 7. Global Cancer Immunotherapy Market, by Application, 2022 & 2032 (USD Billion)
  • Figure 8. Market by Type
  • Figure 9. Global Cancer Immunotherapy Market, by Type, 2022 & 2032 (USD Billion)
  • Figure 10. Market by End-User
  • Figure 11. Global Cancer Immunotherapy Market, by End-User, 2022 & 2032 (USD Billion)
  • Figure 12. Cancer Immunotherapy Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Figure 13. Strategic Analysis - Cancer Immunotherapy Market